275 related articles for article (PubMed ID: 30726732)
21. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
22. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.
Koch C; Engele J
Mol Pharmacol; 2020 Nov; 98(5):577-585. PubMed ID: 32883765
[TBL] [Abstract][Full Text] [Related]
23. Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
Bayrak A; Mohr F; Kolb K; Szpakowska M; Shevchenko E; Dicenta V; Rohlfing AK; Kudolo M; Pantsar T; Günther M; Kaczor AA; Poso A; Chevigné A; Pillaiyar T; Gawaz M; Laufer SA
J Med Chem; 2022 Oct; 65(19):13365-13384. PubMed ID: 36150079
[TBL] [Abstract][Full Text] [Related]
24. CXCR7 as a novel therapeutic target for advanced prostate cancer.
Gritsina G; Yu J
Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058
[TBL] [Abstract][Full Text] [Related]
25. Identification and functional characterization of arginine vasopressin receptor 1A : atypical chemokine receptor 3 heteromers in vascular smooth muscle.
Albee LJ; LaPorte HM; Gao X; Eby JM; Cheng YH; Nevins AM; Volkman BF; Gaponenko V; Majetschak M
Open Biol; 2018 Jan; 8(1):. PubMed ID: 29386406
[TBL] [Abstract][Full Text] [Related]
26. Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model.
Van Loy T; De Jonghe S; Castermans K; Dheedene W; Stoop R; Verschuren L; Versele M; Chaltin P; Luttun A; Schols D
Cell Mol Life Sci; 2022 May; 79(6):293. PubMed ID: 35562519
[TBL] [Abstract][Full Text] [Related]
27. Atypical Chemokine Receptor 3 'Senses' CXC Chemokine Receptor 4 Activation Through GPCR Kinase Phosphorylation.
Schafer CT; Chen Q; Tesmer JJG; Handel TM
bioRxiv; 2023 Mar; ():. PubMed ID: 36865154
[TBL] [Abstract][Full Text] [Related]
28. ACKR3 promotes CXCL12/CXCR4-mediated cell-to-cell-induced lymphoma migration through LTB4 production.
Antonello P; Pizzagalli DU; Foglierini M; Melgrati S; Radice E; Thelen S; Thelen M
Front Immunol; 2022; 13():1067885. PubMed ID: 36713377
[TBL] [Abstract][Full Text] [Related]
29. CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.
Torossian F; Anginot A; Chabanon A; Clay D; Guerton B; Desterke C; Boutin L; Marullo S; Scott MG; Lataillade JJ; Le Bousse-Kerdilès MC
Blood; 2014 Jan; 123(2):191-202. PubMed ID: 24277075
[TBL] [Abstract][Full Text] [Related]
30. α
Albee LJ; Eby JM; Tripathi A; LaPorte HM; Gao X; Volkman BF; Gaponenko V; Majetschak M
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862946
[TBL] [Abstract][Full Text] [Related]
31. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues.
Hoffmann F; Müller W; Schütz D; Penfold ME; Wong YH; Schulz S; Stumm R
J Biol Chem; 2012 Aug; 287(34):28362-77. PubMed ID: 22736769
[TBL] [Abstract][Full Text] [Related]
32. CXCR7 mediates SDF1-induced melanocyte migration.
Lee E; Han J; Kim K; Choi H; Cho EG; Lee TR
Pigment Cell Melanoma Res; 2013 Jan; 26(1):58-66. PubMed ID: 22978759
[TBL] [Abstract][Full Text] [Related]
33. Decreased ACKR3 (CXCR7) function causes oculomotor synkinesis in mice and humans.
Whitman MC; Miyake N; Nguyen EH; Bell JL; Matos Ruiz PM; Chan WM; Di Gioia SA; Mukherjee N; Barry BJ; Bosley TM; Khan AO; Engle EC
Hum Mol Genet; 2019 Sep; 28(18):3113-3125. PubMed ID: 31211835
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a chimeric chemokine as a specific ligand for ACKR3.
Ameti R; Melgrati S; Radice E; Cameroni E; Hub E; Thelen S; Rot A; Thelen M
J Leukoc Biol; 2018 Aug; 104(2):391-400. PubMed ID: 29601107
[TBL] [Abstract][Full Text] [Related]
35. Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.
Yen YC; Schafer CT; Gustavsson M; Eberle SA; Dominik PK; Deneka D; Zhang P; Schall TJ; Kossiakoff AA; Tesmer JJG; Handel TM
Sci Adv; 2022 Jul; 8(28):eabn8063. PubMed ID: 35857509
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.
Szpakowska M; Meyrath M; Reynders N; Counson M; Hanson J; Steyaert J; Chevigné A
Biochem Pharmacol; 2018 Jul; 153():299-309. PubMed ID: 29530506
[TBL] [Abstract][Full Text] [Related]
37. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
38. G protein activation via chemokine (C-X-C motif) receptor 4 and α
Gao X; Majetschak M
FEBS Lett; 2023 Aug; 597(15):2017-2027. PubMed ID: 37395117
[TBL] [Abstract][Full Text] [Related]
39. Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo.
Janssens R; Mortier A; Boff D; Vanheule V; Gouwy M; Franck C; Larsen O; Rosenkilde MM; Van Damme J; Amaral FA; Teixeira MM; Struyf S; Proost P
Oncotarget; 2016 Sep; 7(38):62439-62459. PubMed ID: 27566567
[TBL] [Abstract][Full Text] [Related]
40. The CXCL12/CXCR4/ACKR3 Signaling Axis Regulates PKM2 and Glycolysis.
Luker KE; Luker GD
Cells; 2022 May; 11(11):. PubMed ID: 35681470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
